In vitro activity of BRL 36650, a new penicillin | Zendy

H.W. Van Landuyt | Zendy; A Lambert | Zendy; Johan R. Boelaert | Zendy; B. Gordts | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of BRL 36650, a new penicillin

Author(s) -

H.W. Van Landuyt,

A Lambert,

Johan R. Boelaert,

B. Gordts

Publication year - 1986

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.29.2.362

Subject(s) - aztreonam , ceftazidime , cefotaxime , microbiology and biotechnology , penicillin , antibiotics , pseudomonas aeruginosa , amikacin , acinetobacter , enterobacter , enterobacteriaceae , biology , imipenem , bacteria , antibiotic resistance , biochemistry , escherichia coli , genetics , gene

Compared with four beta-lactam antibiotics and amikacin, BRL 36650 and BMY-28142 were the most active against 509 Enterobacteriaceae, including cefotaxime-resistant isolates and resistant laboratory mutants. BRL 36650 was more active than aztreonam, ceftazidime, and BMY-28142 against Acinetobacter spp., Pseudomonas aeruginosa, and other Pseudomonas spp.; all strains were inhibited by 2 micrograms/ml or less.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research